Хронические критические состояния

Под рубрикой фенотипа «хроническое критическое состояние» объединены различные эндотипы: полинейромиопатия критических состояний, синдром приобретенной слабости в отделении интенсивной терапии, синдром персистирующего воспаления, иммуносупрессии и катаболизма (определение UF SCIRS Исследовательского центра сепсиса и критических заболеваний Университета Флориды [Fr. Moree et al, 2012].

Учитывая увеличение распространенности PICS у пациентов с хроническим критическим состоянием (а также количества повторных госпитализаций, инвалидности и смертности), существует острая необходимость в научных исследованиях таких состояний.

Цель работы: проанализировать данные литературных обзоров, касающихся новых аспектов знаний о хронических критических состояниях, в большей степени, синдрома последствий интенсивной терапии (PICS-CCI).

1. Ohl, K ., Tenbrock, K. Reactive oxygen species as regulators of MDSC-mediated immune suppression / K. Ohl, K. Tenbroch // Frontiers in Immunology. 2018. № 9. Mode of access: https://doi.org/10.3389/fimmu.2018.02499. Date of access: 10.04.2025.

2. Huet, O. Oxidative stress and endothelial dysfunction during sepsis / O. Huet [et al.] // Frontiers in Bioscience. 2011. № 16. P. 1986–1995.

3. Chan, E. L. , Murphy, J. T. Reactive oxygen species mediate endotoxin-induced human dermal endothelial NF-kappaB activation / E. L. Chan, J. T. Murphy // Journalof Surgical Research. 2003. № 111. P. 120–126.

4. Klawitter, F. Mitochondrial Dysfunction in Intensive Care Unit-Acquired Weakness and Critical Illness Myopathy: A Narrative Review / F. Klawitter [et al.] // International Journal of Molecular Sciences. 2023. № 24. Mode of access: https://doi.org/10.3390/ijms24065516. Date of access: 10.04.2025.

5. Puthucheary, Z. A. Acute skeletal muscle wasting in critical illness / Z. A. Puthucheary [et al.] // JAMA. 2013. № 310. P. 1591–1600.

6. Yao, X. Mitochondrial ROS induces cardiac inflammation via a pathway through mtDNA damage in a pneumonia-related sepsis model / X. Yao [et al.] // PLoS ONE. 2015. № 10. Mode of access: https://doi.org/10.1371/journal.pone.0139416. Data of access: 10.04.2025.

7. Gong, Y. Importance of Toll-like receptor 2 in mitochondrial dysfunction during polymicrobial sepsis / Y. Gong [et al.] // Anesthesiology. 2014. № 121. P. 1236–1247.

8. Callahan, L. A .,Supinski, G. S. Sepsis-induced myopathy / L. A. Callahan, G. S. Supinski // Critical Care Medicine. 2009. № 37. P. 354–367.

9. Pannerec, A. Defining skeletal muscle resident progenitors and their cell fate potentials / A. Pannerec [et al.] // Development. 2013. № 140. P. 2879–2891.

10. Yin, H ., Price, F., Rudnicki, M. A. Satellite Cells and the Muscle Stem Cell Niche / H. Yin, F. Price, M. A. Rudnicki // Physiological Reviews. 2013. № 93. –P. 23–67.

11. Abreu , P ., Kowaltowski, A. J. Satellite cell self-renewal in endurance exercise is mediated by inhibition of mitochondrial oxygen consumption / P. Abreu, A. J. Kowaltowski // Journal of Cachexia, Sarcopenia and Muscle. 2020. № 11. P. 1661–1676.

12. Stortz, J. A. Evidence for persistent immune suppression in patients who develop chronic critical illness after sepsis / J. A. Stortz [et al.] // Shock. 2018. № 49. P. 249–258.

13. Jensen, I. J. Sepsis-induced T cell immunoparalysis: The ins and outs of impaired T cell immunity / L. J. Jensen [et al.] // Journal of Immunology. 2018. № 200. P. 1543–1553.

14. Hotchkiss, R. S. Monneret, G., Payen, D. Sepsis-induced immunosuppression: From cellular dysfun ctions to immunotherapy / R. S. Hotchkiss, G. Monneret, D. Payen // Nature Reviews Immunology. 2013. № 13. P. 862–874.

15. Loss, S. H. Chronic critical illness: Are we saving patients or creating victims? / S. H. Loss [et al.] // RevistaBrasileria de TerapiaIntensiva. 2017. № 29. P. 87–95.

16. Gardner, A. K. The development of chronic critical illness determines physical function, quality of life, and long-term survival among early survivors of sepsis in surgical ICUs / A. K. Gardner [et al.] // Critical Care Medicine. 2019. № 47. P. 566–573.

17. Faroogh, M. MSCs and their exosomes: a rapidly evolving approach in the context of cutaneous wounds therapy / M. Faroogh [et al.] // Stem Cell Research & Therapy. 2021. № 12. Mode of access: https://doi.org/10.1186/s13287-02102662-6. Date of access: 10.04.2025.

18. Lotfy, A ., AboQuella, N. M., Wang, H. Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials / A. Lotfy, N. M. AboQuella, H. Wang // Stem Cell Research & Therapy. 2023. № 14. Mode of access: https://doi.org/10.1186/s13287023-03287-7. Date of access: 10.04.2025.

19. Harrell, C. R . Therapeutic Use of Mesenchymal Stem Cell-Derived Exosomes: From Basic Science to Clinics / C. R. Harrell [et al.] // Pharmaceutics. 2020. № 12. Mode of access: https://doi.org/10.3390/pharmaceutics12050474. Data of access: 10.04.2025.

20. Fu, Y . Trophic Effects of Mesenchymal Stem Cells in Tissue Regeneration / Y. Fu [et al.] // Tissue Engineering Part B: Reviews. 2017. № 23. P. 515–528.

21. Harrell, C. R. Molecular Mechanisms Responsible for Anti-inflammatory and Immunosuppressive Effects of Mesenchymal Stem Cell-Derived Factors / C. R. Harrell [et al.] // Advances in Experimental Medicine and Biology. 2019. № 1084. P. 187–206.

22. H uang, D. Role of mesenchymal stem cellderived exosomes in the regeneration of different tissues / H. Defa [et al.] // Journal of Biological Engineering. 2024. № 18. Mode of access: https://doi.org/10.1186/s13036-024-00431-6. Data of access: 10.04.2025.

23. Hade, M. D., Suire, C. N., Suo, Z. Mesenchymal Stem Cell-Derived Exosomes: Applications in Regenerative Medicine / M. D. Hade, C. N. Suire, Z. Suo // Cells. 2021. № 10. Mode of access: https://doi.org/10.3390/cells10081959. Data of access: 10.04.2025.

24. Jahangiri, B . Dual impacts of mesenchymal stem cell-derived exosomes on cancer cells: unravelling complex interactions / B. Jahangiri // Journal of Cell Communication and Signaling. 2023. № 17. P. 1229–1247.

25. Toh, W. S . MSC exosome as a cell-free MSC therapy for cartilage regeneration: implications for osteoarthritis treatment / W. S. Toh [et al.] // Seminars in Cell and Developmental Biology. 2017. № 67. P. 56–64.

26. Heldring, N. Therapeutic potential of multipotent mesenchymal stromal cells and their extracellular vesicles /N. Heldring [et al.] // Human Gene Therapy. 2015. Vol. 26, № 8. P. 506–517.

27. Wang, C. Mesenchymal stromal cell exo somes for drug delivery of prostate cancer treatments: a review / C. Wang [et al.] // Stem Cell Research & Therapy. 2025. № 16. Mode of access: https://doi.org/10.1186/s13287-025-04133-8. Data of access: 10.04.2025.

28. Xun, C. Insight into the proteomic profiling of exosomes secreted by human OM-MSCs reveals a new potential therapy / C. Xun [et al] // Biomedicine & Pharmacotherapy. 2020. № 131. Mode of access: https://doi.org/10.1016/j.biopha.2020.110584. Data of access: 10.04.2025.

29. Hassanzadeh A. Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities / A. Hassanzadeh [et al.] //Stem Cell Research & Therapy. 2021. № 12. Mode of access: https://doi.org/10.1186/s13287-02102378-7. Data of access: 10.04.2025.

30. Deng, H. Lipid, Protein, and MicroRNA Composition Within Mesenchymal Stem Cell-Derived Exosomes / H. Deng [et al.] // Cell Reprogram. 2018. № 20. P. 178–186.

31. Qiu, G. Mesenchymal stem cell-derived extracellular vesicles affect disease outcomes via transfer of microRNAs / G. Qiu [et al.] // Stem Cell Research & Therapy. 2018. № 9. Mode of access: https://doi.org/10.1186/s13287-0181069-9. Data of access: 10.04.2025.

32. Harrell, C. R. Mesenchymal Stem Cell-Derived Exosomes and Other Extracellular Vesicles as New Remedies in the Therapy of Inflammatory Diseases / C. R. Harrell [et al.] // Cells. 2019. № 8. Mode of access: https://doi.org/10.3390/ cells8121605. Data of access: 10.04.2025.

33. Mendt, M. , Rezvani, K., Shpall, E. Mesenchymal stem cell-derived exosomes for clinical use / M. Mendt, K. Rezvani, E. Shpall // Bone Marrow Transplantation. 2019. № 54. P. 789–792.